BRAF and neoplasm: Although depletion of USP9X reduces tumor growth in melanoma cells carrying BRAF or NRAS mutations, its combination with MAPK pathway inhibitors (vemurafenib or MEKi) has been shown to enhance the therapeutic response [52].